keyword
MENU ▼
Read by QxMD icon Read
search

salmeterol

keyword
https://www.readbyqxmd.com/read/28284731/changes-in-asthma-maintenance-therapy-prescribing-patterns-following-the-2006-long-acting-%C3%AE-agonist-fda-drug-warning
#1
Jonathan D Winter, Matthew R Reetz, J William Kerns, Katherine M Winter, Roy T Sabo, Scott D Krugman
PURPOSE: The US Food and Drug Administration issued a boxed warning on all products containing a long-acting β-agonist (LABA) in March 2006, after the findings from a trial suggested an increased risk for death in patients treated with salmeterol monotherapy. Almost nothing is known about the impact of this warning on LABA prescribing patterns or on clinicians' approaches to asthma maintenance therapy. METHODS: A cohort of asthmatic adults on LABA therapy was retrospectively identified from a Baltimore-area Medicaid data warehouse...
March 8, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28278391/blood-eosinophils-and-response-to-maintenance-copd-treatment-data-from-the-flame-trial
#2
Nicolas Roche, Kenneth R Chapman, Claus F Vogelmeier, Felix J F Herth, Chau Thach, Robert Fogel, Petter Olsson, Francesco Patalano, Donald Banerji, Jadwiga A Wedzicha
RATIONALE: Post-hoc analyses suggest that blood eosinophils have potential as a predictive biomarker of inhaled corticosteroid efficacy in the management of chronic obstructive pulmonary disease. OBJECTIVES: We prospectively investigated the value of blood eosinophils as a predictor of responsiveness to an inhaled corticosteroid/long-acting β2-agonist combination versus a long-acting β2-agonist/long-acting muscarinic antagonist combination for exacerbation prevention...
March 9, 2017: American Journal of Respiratory and Critical Care Medicine
https://www.readbyqxmd.com/read/28276739/the-inca-tm-inhaler-compliance-assessment-tm-a-comparison-with-established-measures-of-adherence
#3
Catherine Moran, Frank Doyle, Imran Sulaiman, Kathleen Bennett, Garrett Greene, Gerard J Molloy, Richard B Reilly, Richard W Costello, Lisa Mellon
OBJECTIVE: To compare the Inhaler Compliance Assessment(TM) (INCA(TM)), a novel audio-recording device objectively measuring timing and proficiency of inhaler use, against established adherence measures, and explore its discriminant and predictive validity. DESIGN: Prospective observational study; 184 chronic obstructive pulmonary disease (COPD) patients used an INCA(TM)-enabled salmeterol/fluticasone inhaler for one-month post-hospital discharge. MAIN OUTCOME MEASURES: INCA(TM) (Attempted, Attempted Interval, Actual) adherence correlated with Doses Used Rate, self-reported adherence and prescription refill for concurrent validity...
February 28, 2017: Psychology & Health
https://www.readbyqxmd.com/read/28220767/asthma-control-in-adult-patients-treated-with-a-combination-of-inhaled-corticosteroids-and-long%C3%A2-acting-%C3%AE-2%C3%A2-agonists-a-prospective-observational-study
#4
Barbara Rogala, Paweł Majak, Joanna Glück, Tomasz Dębowski
INTRODUCTION    Asthma is a highly prevalent disease that often requires maintenance therapy. Combined inhaled corticosteroid (ICS) and long‑acting β2‑agonist (LABA) inhalers are one of the available maintenance treatment options. OBJECTIVES    This prospective observational study aimed to assess asthma control in patients treated with ICS/LABA inhalers and to identify factors related to optimal asthma control. PATIENTS AND METHODS    The study included 5789 asthmatic patients from Poland, treated with one of the following ICS/LABA inhalers at clinically appropriate doses: beclomethasone/formoterol, fluticasone/ salmeterol, or budesonide/formoterol...
January 18, 2017: Pol Arch Intern Med
https://www.readbyqxmd.com/read/28186150/glcci1-rs37973-a-potential-genetic-predictor-of-therapeutic-response-to-inhaled-corticosteroids-in-chinese-chronic-obstructive-pulmonary-disease-patients
#5
Yuan Lei, Yiping Gao, Jinkun Chen, Miao Li, Xiaomei Wu, Qin Ning, Jianping Zhao, Weining Xiong, Yongjian Xu, Jungang Xie
Inhaled corticosteroids (ICSs) are widely prescribed in chronic obstructive pulmonary disease (COPD). However, little is known about predictors of ICSs therapeutic response. To investigate whether the variation in glucocorticoid-induced transcript 1 (GLCCI1) rs37973 is associated with ICS efficacy. A total of 204 clinically stable COPD patients were recruited and administered to inhaled fluticasone propionate/salmeterol combination (500/50 ug, twice daily) for 24 weeks. We genotyped the functional rs37973 and mainly assessed its effects on changes in lung function...
February 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28176893/indacaterol-glycopyrronium-versus-salmeterol-fluticasone-in-asian-patients-with-copd-at-a-high-risk-of-exacerbations-results-from-the-flame-study
#6
Jadwiga A Wedzicha, Nanshan Zhong, Masakazu Ichinose, Michael Humphries, Robert Fogel, Chau Thach, Francesco Patalano, Donald Banerji
BACKGROUND: The FLAME study demonstrated that indacaterol/glycopyrronium (IND/GLY), the fixed-dose combination of a long-acting β2-agonist (LABA, IND) and a long-acting muscarinic antagonist (LAMA, GLY), was superior to salmeterol/fluticasone combination (SFC) in preventing exacerbations in COPD patients with a high risk of exacerbations. In this study, we report a prespecified analysis of the efficacy and safety of IND/GLY versus SFC in Asian patients from the FLAME study. PATIENTS AND METHODS: Patients from Asian centers with moderate-to-very severe COPD and ≥1 exacerbation in the previous year from the 52-week, randomized FLAME study were included...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28176892/comparative-efficacy-of-long-acting-%C3%AE-2-agonists-as-monotherapy-for-chronic-obstructive-pulmonary-disease-a-network-meta-analysis
#7
James F Donohue, Keith A Betts, Ella Xiaoyan Du, Pablo Altman, Pankaj Goyal, Dorothy L Keininger, Jean-Bernard Gruenberger, James E Signorovitch
PURPOSE: Long-acting β2-agonists (LABAs) have demonstrated efficacy in patients with COPD in clinical trials. The purpose of this study was to assess the comparative efficacy of all available dosages of all LABA monotherapies using a network meta-analysis. METHODS: A systematic literature review identified 33 randomized controlled trials of LABA monotherapies (salmeterol 50 μg twice daily [BID]; formoterol 12 μg BID; indacaterol 75, 150, and 300 μg once daily [OD]; olodaterol 5 and 10 μg OD, and vilanterol 25 μg OD)...
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28159683/measurement-of-the-raman-spectra-and-hygroscopicity-of-four-pharmaceutical-aerosols-as-they-travel-from-pressurised-metered-dose-inhalers-pmdi-to-a-model-lung
#8
N Davidson, H-J Tong, M Kalberer, P C Seville, A D Ward, M K Kuimova, F D Pope
Particle inhalation is an effective and rapid delivery method for a variety of pharmaceuticals, particularly bronchodilation drugs used for treating asthma and COPD. Conditions of relative humidity and temperature inside the lungs are generally very different from the outside ambient air, with the lung typically being warmer and more humid. Changes in humidity, from inhaler to lung, can cause hygroscopic phase transitions and particle growth. Increasing particle size and mass can negatively affect particle deposition within the lung leading to inefficient treatment, while deliquescence prior to impaction is liable to accelerate drug uptake...
January 31, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/28141723/anxiety-associated-with-asthma-exacerbations-and-overuse-of-medication-the-role-of-cultural-competency
#9
Yousuke T Horikawa, Tina Y Udaka, Janet K Crow, John I Takayama, Martin T Stein
Toshi, a 14-year-old Japanese boy, had uncontrolled asthma after relocating from Japan with his family 1 year ago. In Japan, he was diagnosed with moderate, persistent asthma, which was controlled with salmeterol and albuterol on an as needed basis. Since moving to the United States, Toshi complained of frequent dyspnea.Initially, he was seen by a Japanese physician who prescribed 200 mg of fluticasone 3 times a day and albuterol nebulization as needed. When Toshi came to the Pediatric Primary Care Clinic, he reported using his nebulizer up to 25 times daily...
February 2017: Journal of Developmental and Behavioral Pediatrics: JDBP
https://www.readbyqxmd.com/read/28138230/erratum-comparative-analysis-of-budesonide-formoterol-and-fluticasone-salmeterol-combinations-in-copd-patients-findings-from-a-real-world-analysis-in-an-italian-setting-corrigendum
#10
(no author information available yet)
[This corrects the article on p. 2749 in vol. 11, PMID: 27853362.].
2017: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28115223/assessment-of-the-efficacy-and-safety-of-fluticasone-propionate-and-salmeterol-delivered-as-a-combination-dry-powder-via-a-capsule-based-inhaler-versus-a-multi-dose-inhaler-in-patients-with-chronic-obstructive-pulmonary-disease
#11
Robert Chan, Ana R Sousa, Peter Hynds, Farshid Homayoun-Valiani, Dawn Edwards, Maggie Tabberer
BACKGROUND: This study tested the clinical non-inferiority of the fluticasone propionate/salmeterol combination 50/250 μg (FSC) Rotacaps(®)/Rotahaler(®) system, a single unit dose inhaler, with the multi-dose FSC Diskus(®) inhaler in adults with chronic obstructive pulmonary disease (COPD). METHODS: This multi-centre, randomised, double-blind, double-dummy, two-way cross-over study compared 12 weeks' treatment of FSC administered twice daily using Rotacaps/Rotahaler or Diskus...
January 20, 2017: Pulmonary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/28097668/detection-and-pharmacokinetics-of-salmeterol-in-thoroughbred-horses-following-inhaled-administration
#12
S J Fenwick, P R Hincks, J P Scarth, M E Wieder, L L Hillyer, S W Paine
Salmeterol is a man-made beta-2-adrenergic receptor agonist used to relieve bronchospasm associated with inflammatory airway disease in horses. Whilst judicious use is appropriate in horses in training, they cannot race with clinically effective concentrations of medications under the British Horseracing Authority's Rules of Racing. Salmeterol must therefore be withdrawn prior to race day and pharmacokinetic (PK) studies used to establish formal detection time advice. Salmeterol xinafoate (Serevent Evohaler(®) ) was administered (0...
January 17, 2017: Journal of Veterinary Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28049170/airway-inflammation-in-copd-after-long-term-withdrawal-of-inhaled-corticosteroids
#13
Lisette I Z Kunz, Nick H T Ten Hacken, Thérèse S Lapperre, Wim Timens, Huib A M Kerstjens, Annemarie van Schadewijk, Judith M Vonk, Jacob K Sont, Jiska B Snoeck-Stroband, Dirkje S Postma, Peter J Sterk, Pieter S Hiemstra
Long-term treatment with inhaled corticosteroids (ICS) might attenuate lung function decline and decrease airway inflammation in a subset of patients with chronic obstructive pulmonary disease (COPD), and discontinuing ICS treatment could result in further lung function decline. We hypothesised that airway inflammation increases after ICS withdrawal following long-term ICS treatment in COPD.In the GLUCOLD-1 study (GL1), 114 patients with moderate-severe COPD were randomised to 6-month or 30-month treatment with fluticasone propionate (500 µg twice daily), 30-month treatment with fluticasone/salmeterol (500/50 µg twice daily) or placebo...
January 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28033454/enantioselective-disposition-of-r-salmeterol-and-s-salmeterol-in-urine-following-inhaled-dosing-and-application-to-doping-control
#14
Glenn A Jacobson, Morten Hostrup, Christian K Narkowicz, David S Nichols, E Haydn Walters
Salmeterol (USAN, INN, BAN) is a long-acting beta2-adrenoceptor agonist (LABA) widely used in the treatment of airways disease. Although salmeterol is permitted via inhalation by athletes and supratherapeutic dosing may enhance performance, no urine threshold has been established by the World Anti-Doping Agency (WADA). Salmeterol is a chiral compound consisting of (R)- and (S)-enantiomers, normally administered as racemic (rac-) mixture via inhalation. Levels of rac-salmeterol in urine are often below detectable levels and there is surprisingly little information regarding the enantioselectivity of salmeterol pharmacokinetics...
November 7, 2016: Drug Testing and Analysis
https://www.readbyqxmd.com/read/28008244/indacaterol-glycopyrronium-in-symptomatic-patients-with-copd-gold-b-and-gold-d-versus-salmeterol-fluticasone-illuminate-lantern-pooled-analysis
#15
Claus Vogelmeier, Nanshan Zhong, Michael J Humphries, Karen Mezzi, Robert Fogel, Giovanni Bader, Francesco Patalano, Donald Banerji
BACKGROUND: Indacaterol/glycopyrronium (IND/GLY) is approved for maintenance treatment of adult patients with COPD. This post hoc analysis explored the efficacy and safety of IND/GLY versus salmeterol/fluticasone (SFC) in symptomatic (Global Initiative for Chronic Obstructive Lung Disease [GOLD] B and GOLD D) patients with moderate-to-severe COPD. PATIENTS AND METHODS: Data from LANTERN and ILLUMINATE studies were pooled and analyzed. In both studies, symptomatic COPD patients were randomized to once-daily IND/GLY 110 μg/50 μg or twice-daily SFC 50 μg/500 μg...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/28008243/efficacy-of-tiotropium-olodaterol-fixed-dose-combination-in-copd
#16
REVIEW
Eric Derom, Guy G Brusselle, Guy F Joos
Tiotropium-olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled fixed-dose combination (FDC) of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA), commercialized under the name of Spiolto or Stiolto. The efficacy of tiotropium-olodaterol 5-5 μg once daily in adult patients with COPD was documented in eleven large, multicenter trials of up to 52 weeks duration. Tiotropium-olodaterol 5-5 μg not only improved spirometric values to a significantly greater extent than placebo but also resulted in statistically significant beneficial effects on dyspnea, markers of hyperinflation, use of rescue medication, health-related quality of life, and exercise endurance...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/27965772/once-daily-fluticasone-furoate-vilanterol-versus-twice-daily-combination-therapies-in-asthma-mixed-treatment-comparisons-of-clinical-efficacy
#17
Henrik Svedsater, Gillian Stynes, Jaro Wex, Lucy Frith, David Leather, Emanuela Castelnuovo, Michelle Detry, Scott Berry
BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) is a once-daily inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) combination. FF/VI, 92/22mcg and 184/22mcg, are approved in Europe as maintenance therapy in persistent asthma. We report data from mixed treatment comparisons (MTC) of once-daily FF/VI against established twice-daily ICS/LABA combination therapies on clinical efficacy outcomes. METHODS: Data from 31 parallel-group randomised controlled trials (RCTs) of ICS/LABA, of ≥8 weeks' duration in patients aged ≥12 years with asthma, identified by systematic review, were analysed using covariate-adjusted Bayesian hierarchical models for four efficacy outcomes (primary analysis)...
2016: Asthma research and practice
https://www.readbyqxmd.com/read/27959747/salmeterol-and-fluticasone-propionate-in-children-with-asthma
#18
LETTER
Antonio Nieto, Ángel Mazón, María Nieto
No abstract text is available yet for this article.
December 1, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27959746/salmeterol-and-fluticasone-propionate-in-children-with-asthma
#19
LETTER
David A Stempel, Stanley J Szefler, Steven J Pascoe
No abstract text is available yet for this article.
December 1, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/27920517/superiority-of-tiotropium-plus-olodaterol-in-comparison-with-salmeterol-plus-fluticasone
#20
COMMENT
Tomohiro Tamura, Hiroaki Satoh
No abstract text is available yet for this article.
2016: International Journal of Chronic Obstructive Pulmonary Disease
keyword
keyword
111390
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"